2,442 reports of this reaction
2.1% of all OCTREOTIDE ACETATE reports
#10 most reported adverse reaction
MALIGNANT NEOPLASM PROGRESSION is the #10 most commonly reported adverse reaction for OCTREOTIDE ACETATE, manufactured by Novartis Pharmaceuticals Corporation. There are 2,442 FDA adverse event reports linking OCTREOTIDE ACETATE to MALIGNANT NEOPLASM PROGRESSION. This represents approximately 2.1% of all 115,420 adverse event reports for this drug.
OCTREOTIDE ACETATE has an overall safety score of 85 out of 100. Patients taking OCTREOTIDE ACETATE who experience malignant neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT NEOPLASM PROGRESSION is a less commonly reported adverse event for OCTREOTIDE ACETATE, but still significant enough to appear in the safety profile.
In addition to malignant neoplasm progression, the following adverse reactions have been reported for OCTREOTIDE ACETATE:
The following drugs have also been linked to malignant neoplasm progression in FDA adverse event reports:
MALIGNANT NEOPLASM PROGRESSION has been reported as an adverse event in 2,442 FDA reports for OCTREOTIDE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT NEOPLASM PROGRESSION accounts for approximately 2.1% of all adverse event reports for OCTREOTIDE ACETATE, making it a notable side effect.
If you experience malignant neoplasm progression while taking OCTREOTIDE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.